



At IDRI, our mission is to translate science into global health solutions. We develop vaccines, diagnostics, and therapeutic products that address the world's most neglected infectious diseases.

Darrick Carter, PhD

Vice President, Adjuvant Technology

Darrick Carter is the Vice President of Adjuvant Technology at IDRI. His work centers on new immunomodulatory agents and formulations, as well as the process development necessary to take vaccines and therapeutic candidates from the lab to the clinic.

Darrick is a biochemist/biophysicist with over 10 years of experience in the biotechnology industry developing therapeutics and vaccines. He has founded five companies, starting with a sole proprietorship biotech/internet startup, Proteinchemist.com, in 2001. Darrick previously worked at Corixa Corporation, where he led a new tuberculosis vaccine into human clinical trials and assisted as group leader for analytical biochemistry working on adjuvants and a commercial, radiolabeled mAb for non-Hodgkins lymphoma. In 2005, he founded and served as CEO of Protein Advances Inc., a bioinformatics company with proprietary drug discovery technologies using artificial neural nets. Darrick also served as CSO at a specialty pharmaceutical company focused on drug and device combinations, is a founding member of a company focused on immunotherapy in oncology, and a founding member of a device company working on inflammatory disorders. Darrick sits on the Scientific Advisory Boards of three local biotech companies and hosts a web site for protein chemists. He has authored over 30 peer-reviewed papers and is inventor/co-inventor on more than 160 patent applications and issued patents.

Darrick received his BSc summa cum laude from the department of Biochemistry and Biophysics at Oregon State University. He received his PhD from the Department of Biochemistry and Molecular Biology at Oregon Health Sciences University.